Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis

医学 荟萃分析 哮喘 梅德林 重症监护医学 内科学 政治学 法学
作者
Amy Shackleford,Liam Gabriel Heaney,Charlene Redmond,P. Jane McDowell,John Busby
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:13 (1): 23-34 被引量:175
标识
DOI:10.1016/s2213-2600(24)00293-5
摘要

Background Clinical remission has emerged as an important treatment goal in severe asthma; however, studies have reported variable attainment due to differences in study populations, definitions, and methods. We aimed to perform a systematic review and meta-analysis of clinical remission attainment, definitions, and correlates among patients with severe asthma who have been treated with biologics. Methods In this systematic review and meta-analysis, we searched Web of Science, Embase, and MEDLINE, using the keywords "asthma" and "remission", for studies published between database inception and June 13, 2024, that reported clinical remission among patients with severe asthma treated with biologics. Studies were eligible for inclusion in both the systematic review and meta-analysis if they were published in English language peer-reviewed journals and reported rates of clinical remission for patients treated with biologics for severe asthma. There were no limitations by study design. Two reviewers independently screened identified papers (AS and CR), with disagreements resolved through consensus or referral to a third reviewer (JB). Study-level data on study characteristics, clinical remission definitions, clinical remission attainment, and the potential correlates of clinical remission were extracted independently by two reviewers (AS and CR) using Covidence. We defined a three-component definition of clinical remission, which included use of maintenance oral corticosteroids, exacerbations, and asthma symptom burden, and a four-component definition, which additionally included lung function. We meta-analysed the rate of attainment of clinical remission and assessed the correlates of clinical remission using DerSimonian-Laird random-effects models. Statistical heterogeneity was assessed using the I 2 statistic. This study was registered with PROSPERO, CRD42024507233. Findings Our search identified 3014 potentially eligible studies, of which 1812 were screened. 25 studies were included, which reported 28 analyses of clinical remission attainment. 68 definitions of clinical remission were identified, of which 48 were unique. Little consensus was found between studies in terms of the clinical remission definition, particularly for symptoms and lung function. Eight analyses used the three-component definition of clinical remission and 25 used the four-component definition. The pooled proportion of patients who attained clinical remission was 38% (95% CI 29–47; I 2 =93%) for the three-component definition and 30% (27–34; I 2 =83%) for the four-component definition. Several pulmonary factors were associated with lower clinical remission rates, including worse FEV 1 (odds ratio 0·09 [95% CI 0·01–0·92]; I 2 =87%), worse asthma symptoms (0·23 [0·17–0·33]; I 2 =0%), longer asthma duration (0·49 [0·32–0·76]; I 2 =22%), and use of maintenance oral corticosteroids (0·57 [0·40–0·79]; I 2 =49%). The presence of comorbidities, in particular depression (0·38 [0·23–0·61]; I 2 =6%) and obesity (0·41 [0·31–0·54]; I 2 =0%), were important non-pulmonary barriers to clinical remission. Interpretation Clinical remission is an achievable goal for a minority of patients with severe asthma treated with biologics. Definitions of clinical remission varied substantially between studies, and materially affected attainment, suggesting an urgent need for further consensus-driven definitions. Longer disease duration, higher asthma severity, and the presence of comorbidities were identified as important barriers to clinical remission, suggesting that earlier intervention with effective treatments and a broader treatable traits approach might improve outcomes. Funding Health Data Research UK, Inflammation and Immunity driver project.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Eikps完成签到,获得积分10
刚刚
whc发布了新的文献求助10
1秒前
腾腾发布了新的文献求助10
2秒前
ikun完成签到,获得积分10
2秒前
3秒前
3秒前
限量款小辰完成签到,获得积分20
4秒前
可乐完成签到,获得积分10
4秒前
5秒前
暴躁的飞风完成签到 ,获得积分10
5秒前
小二郎的应助被Sledge采纳,获得10
5秒前
666完成签到,获得积分10
6秒前
程科杰发布了新的文献求助30
6秒前
6秒前
Zhuxiaole完成签到,获得积分10
6秒前
北落师门完成签到,获得积分10
9秒前
666发布了新的文献求助10
9秒前
9秒前
完美世界的应助被欢呼的梦蕊采纳,获得20
10秒前
10秒前
MZ发布了新的文献求助30
11秒前
12秒前
SciGPT的应助被kk采纳,获得10
12秒前
无极微光的应助被逢投必中采纳,获得20
12秒前
ASCK完成签到,获得积分0
12秒前
zishuqio完成签到,获得积分10
12秒前
12秒前
逃跑的炸鸡完成签到 ,获得积分10
13秒前
传奇3的应助被淡定的伊采纳,获得10
13秒前
icey完成签到,获得积分10
14秒前
涤烦子完成签到,获得积分10
14秒前
华子完成签到 ,获得积分10
15秒前
15秒前
无言发布了新的文献求助10
16秒前
博纳清完成签到 ,获得积分10
16秒前
大模型的应助被tiansun采纳,获得50
16秒前
Meteor636完成签到 ,获得积分10
17秒前
勤奋花卷发布了新的文献求助10
17秒前
XYM发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160632
求助须知:如何正确求助?哪些是违规求助? 9555512
关于积分的说明 21728801
捐赠科研通 7750444
什么是DOI,文献DOI怎么找? 3427429
关于科研通互助平台的介绍 2552456
邀请新用户注册赠送积分活动 2471817